BioArctic receives Orphan Drug Designation for exidavnemab the US
Go back to BioArctic receives Orphan Drug Designation for exidavnemab the US| BARNES GROUP, Inc. (NYSE: B) | Delayed: 41.23 +1.10 (2.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $40.13 | 52 Week High | $44.27 | |||
| Open | $41.38 | 52 Week Low | $30.07 | |||
| Day High | $41.65 | P/E | 31.47 | |||
| Day Low | $40.63 | EPS | $1.31 | |||
| Volume | 13,772,081 | |||||
| BIOAMBER, Inc. (NASDAQ: BIOA) | Delayed: 10.48 -0.19 (1.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.67 | 52 Week High | $8.73 | |||
| Open | $10.78 | 52 Week Low | $2.86 | |||
| Day High | $10.95 | P/E | N/A | |||
| Day Low | $10.43 | EPS | $-3.82 | |||
| Volume | 614,579 | |||||
